Clinical Trials Browser

OTHER × Ovarian Neoplasms × SHR-1701 × Clear all

NCT07355010 2026-01-21

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms